Evidence map›Paper›PMID 41185747›Full record

ArticleInternational journal of nanomedicine2025

Strain-Specific

Priyanka Singh, Ivan Mijakovic

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Green-synthesizedRSC advances · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Priyanka SinghThe Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark, Kogens Lyngby, DK-2800, Denmark.ORCID 0000-0001-7654-5339
Ivan MijakovicThe Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark, Kogens Lyngby, DK-2800, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Nanoparticles, particularly silver and gold nanoparticles, have emerged as powerful tools for improving drug stability, bioavailability, and targeted delivery in medical applications. With the increasing global demand for nanoparticles (NPs), sustainable and biocompatible production methods are crucial. This study investigates the biosynthesis of silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) using two genetically related bacterial strains, Methods: AgNPs were synthesized extracellularly from bacterial cell supernatants, whereas AuNPs were generated intracellularly by incubating washed cell pellets with gold salt. The nanoparticles were characterized using UV-Vis spectroscopy, sp-ICP-MS, TGA, SEM, TEM, FTIR, MALDI-TOF, zeta potential, and AFM. Antibacterial activity against Results: Both strains synthesized AgNPs and AuNPs, but Conclusion: This study highlights the superior NPs biosynthesis capacity and antibacterial potency of the wild-type strain

Indexed as

Anti-Bacterial AgentsBacillus subtilisMetal NanoparticlesSilverDrug Resistance, Multiple, BacterialEscherichia coliGoldMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsGoldSilverantimicrobial resistanceB. subtilisgold nanoparticlesmultidrug-resistant pathogenssilver nanoparticlessimultaneous productionstability

Identifiers

PMID41185747
PMCPMC12579842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.